The possibilities of improvement of diagnosis of patients with post-infarction cardiosclerosis

Abstract

The article presents analysis of endovascular treatment of 166 patients with post-infarction cardiosclerosis. It is proved that in patients with post-infarction cardiosclerosis having vital but hibernated myocardium in the zone of affected artery the restoration of coronary blood flow permits not only to eliminate signs of chronic ischemia, to slow down post-infarction remodeling of heart but to restore lost functions of hibernated myocardium. On the whole, these occurrences can benevolently influence the prognosis of disease. The reliable dependence between terms of restoration of coronary blood low and function of hibernated myocardium is established.

Keywords

hibernated myocardium / vitality of myocardium / post-infarction cardiosclerosis / post-infarction remodeling

References

[1] Доклад Министерства Здравоохранения Российской Федерации "Заболеваемость всего населения России в 2013 году". Часть III. М.: Минздрав РФ и ЦНИИИОЗ МЗ РФ; 2014.

[2] Кузнецов В.А., Зырянов И.П., Гультяева Е.П., Ярославская Е.И., Пушкарев Г.С., Енина Т.Н. и др. Нужно ли использовать тюменский опыт выполнения интракоронарных чрескожных вмешательств на Дальнем Востоке? Дальневосточный медицинский журнал. 2012; 2: 33-6.

[3] Тархановский А. Механизм работы: ОКС в Татарстане. Новости кардиологии. 2014; 2: 2-3.

[4] Fox K.A., Anderson F.A. Jr., Goodman S.G., Steg P.G., Pieper K., Quill A. et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat. Clin. Pract. Cardiovasc. Med. 2008; 5 (9): 580-9. 14.

[5] Depre C., Kim S.J., John A.S., Huang Y., Rimoldi O.E., Pepper J.R. et al. Program of cell survival underlying human and experimental hibernating myocardium. Circ. Res. 2004; 95 (4): 433-40.

[6] Bax J.J., Poldermans D., Elhendy A., Cornel J.H., Boersma E. et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J. Am. Coll. Cardiol. 1999; 34: 163-9.

[7] Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Am. Coll. Cardiol. 2002; 39: 1151-8.

[8] Erne P., Schoenenberger A.W., Burckhardt D., Zuber M., Kiowski W., Buser P.T. et al. Effects of Percutaneous Coronary Interventions in Silent Ischemia After Myocardial Infarction. The SWISSI II randomized controlled trial. JAMA. 2007; 297 (18): 1985-91.

[9] Pagano D., Lewis M., Townend J.N., Davies P., Camici P.G., Bonser R.S. Coronary revascularisation for postischemic heart failure: how myocardial viability affects survival. Heart. 1999; 82: 684-8.

[10] Boden W.E., O'rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., 18 Kostuk W. et al. COURAGE trial co-principal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation 19 (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am. Heart J. 2006; 151 (6): 1173-9.

[11] Boden W.M., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. et al. Optimal Medical Therapy with or without PCI for 20 stable coronary disease. N. Engl. J. Med. 2007; 356 (15): 1503-16.

[12] Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am. Heart J. 2008; 156 (3): 528-36.

[13] Sobel B.E. Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial. Coron. Artery Dis. 2010; 21 (3): 189-98.

[14] Shaw L.J., Berman D.S., Maron D.J., COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117 (10): 1283-91.

[15] Tonino P.A., Fearon W.F., De Bruyne B., Oldroyd K.G., Leesar M.A., Ver Lee P.N. et al. Angiographic versus functional severity of coronary artery stenosis in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J. Am. Coll. Cardiol. 2010; 55 (25): 2816-21.

[16] Frohlich G., Redwood S., Rakhit R., MacCarthy P.A., Lim P., Crake T. et al. Long-term survival in patients undergoing percutaneous interventions with or without intracoronary pressure wire guidance or intracoronary ultrasonographic imaging. J. A. M. A. Intern. Med. 2014; 174 (8): 1360-6.

[17] Sicari R.I., Nihoyannopoulos P., Evangelista A., Kasprzak J., Lancellotti P., Poldermans D. et al. European Association of Echocardiography. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur. J. Echocardiogr. 2008; 9 (4): 415-37.

[18] Lau J.M., Laforest R., Priatna A., Sharma S., Zheng J., Gropler R.J. et al. Demonstration of intermittent ischemia and stunning in hibernating myocardium. J. Nucl. Cardiol. 2013; 20 (5): 908-12.

[19] Murphy J.C., Hansen P.S., Bhindi R., Figtree G.A., Nelson G.I., Ward M.R. Cost benefit for assessment of ntermediate coronary stenosis with fractional flow reserve in public and private sectors in Australia. Heart Lung Circ. 2014: 23 (9): 807-10.

[20] Malek L.A., Silva J.C., Bellenger N.G., Nicolau J.C., Klopotowski M., Spiewak M. et al. Late percutaneous coronary intervention for an occluded infarct-related artery in patients with preserved infarct zone viability: a pooled analysis of cardiovascular magnetic resonance studies. Cardiol. J. 2013; 20 (5): 552-9.

RIGHTS & PERMISSIONS

Eco-Vector